News & Announcements 2017-04-28T04:34:21+00:00

News & Announcements

   
22/11/2017FierceBiotech News article: FDA lifts second trial hold for Prescient’s lead drug, with one to goLink
21/11/2017Edison Investment Research - Clinical Development UpdatePDF
20/11/2017Results of Annual General MeetingPDF
20/11/2017AGM Chairman AddressPDF
20/11/2017AGM PresentationPDF
06/11/2017PTX to resume Clinical Trial of PTX-200 in Ovarian CancerPDF
27/10/2017September 2017 Appendix 4C - QuarterlyPDF
20/10/2017Notice of Annual General Meeting/Proxy FormPDF
05/10/2017Investor Presentation - October 2017PDF
03/10/2017PTX-100 to Re-enter Trials in Hematology NichePDF
04/09/2017Prescient to resume AML trialPDF
29/08/2017Appendix 4G and Corporate Governance StatementPDF
29/08/2017Appendix 4E and 2017 Annual ReportPDF
01/08/2017Investor Newsletter - August 2017PDF
26/07/2017June 2017 Appendix 4C - QuarterlyPDF
30/06/2017Paul Hopper moves to Non-Executive DirectorPDF
22/06/2017Gold Coast Investor Conference PresentationPDF
19/06/2017Novel PTX-100 Cancer Approach Published in NaturePDF
29/05/2017Clinical Trial UpdatePDF
16/05/2017PTX Broker PresentationPDF
12/05/2017European Patent Granted for PTX-200PDF
08/05/2017Kansas University Joins PTX's AML TrialPDF
1/05/2017AML Clinical Trial Conference call with Jeff Lancet and Said SebtiLISTEN
READ TRANSCRIPT
1/05/2017FDA Grants Orphan Drug Designation for PTX-200 in Acute Myeloid LeukemiaPDF
20/04/2017 AML Update - Conference call with Principal InvestigatorPDF
06/04/2017 Successful Completion of Phase 1b Breast Cancer TrialPDF
04/04/2017 Trading HaltPDF
28/03/2017Response to ASX Price QueryPDF
16/03/2017 Three Additional US Patents GrantedPDF
15/03/2017ROTH Conference PresentationPDF
15/03/2017 PTX presentation for 29th Annual ROTH ConferencePDF
08/03/2017First Cohort Successfully Completed in Phase 1b/2 AML TrialPDF
03/03/2017 PTX to present at 29th Annual ROTH ConferencePDF
23/02/2017 Appendix 4D and Half Year Financial ReportPDF
25/01/2017December 2016 Appendix 4C - QuarterlyPDF
11/01/2017Investor Presentation January 2017PDF
11/01/2017PTX to present at Biotech Showcase 2017 in San FranciscoPDF
DATEHEADLINEDOWNLOAD
2016/01/08FDA Allows PTX IND for Leukemia Phase Ib & II TrialsPDF
2016/01/11PTX to present at Biotech Showcase 2016 in San FranciscoPDF
2016/01/14Yale Hematolgy Leader Joins PTX Scientific Advisory BoardPDF
2016/01/19Response to Price QueryPDF
2016/01/21PTX Presents at NobleCon12PDF
2016/01/25 December 2015 Appendix 4CPDF
2016/02/05Appendix 3B
New issue announcement
PDF
2016/02/15Steven Yatomi-Clarke Appointed CEOPDF
2016/02/17Prescient Therapeutics Limited
Appendix 4D
Half-year report
PDF
2016/02/17PTX-200 Breast Cancer Trial ProgressesPDF
2016/03/02 Prescient Therapeutics Featured on Bloomberg’s
The RedChip Money Report
PDF
2016/03/03Edison Investment Research Initiates CoveragePDF
2016/03/31RedChip Issues Research on Prescient TherapeuticsPDF
2016/04/13Blue chip US science yielding
a deep clinical pipeline
PDF
2016/04/21March 2016 Appendix 4CPDF
2016/05/18Appendix 3B
New issue announcement,
application for quotation of additional securities
and agreement
PDF
2016/05/18PARTICIPATION IN PRO-RATA NON-RENOUNCEABLE RIGHTS ISSUEPDF
2016/05/18PARTICIPATION IN PRO-RATA NON-RENOUNCEABLE RIGHTS ISSUEPDF
2016/05/18PARTICIPATION IN PRO-RATA NON-RENOUNCEABLE RIGHTS ISSUEPDF
2016/05/18Prospectus - Offer DocumentPDF
2016/05/18PTX SECURES $7.0 M CAPITAL RAISINGPDF
2016/05/23Notice of General MeetingPDF
2016/05/24Tranche 1 Capital Raising Complete and Appendix 3BPDF
2016/05/26Notice of change of interests of substantial holderPDF
2016/06/01Rights Issue UpdatePDF
2016/06/03Replacement ProspectusPDF
2016/06/06Despatch of Pro-rata Rights Issue Offer DocumentsPDF
2016/06/15Yale Joins PTX’s Phase 1b/2 AML Clinical TrialPDF
2016/06/16Extension of Closing Date of Entitlement OfferPDF
2016/06/22Results of MeetingPDF
2016/06/23Tranche 2 Capital Raising Complete and Appendix 3BPDF
2016/06/24Becoming a Substantial holderPDF
2016/06/24Change in Substantial holdingPDF
2016/06/28Becoming a Substantial holderPDF
2016/06/29Entitlement Offer Closure and Shortfall NotificationPDF
2016/06/30Completion of Entitlement Issue AllotmentPDF
2016/07/01Appendix 3Y
Change of Director’s Interest Notice
PDF
2016/07/01Notice of ceasing to be a substantial holderPDF
2016/07/05Notice of change of interests of substantial holderPDF
2016/07/07Notice of change of interests of substantial holderPDF
2016/07/12Shortfall Placement OversubscribedPDF
2016/07/18Section 708A Notice and Appendix 3BPDF
2016/07/20Change to Exercise Price of OptionsPDF
2016/07/20June 2016 Appendix 4CPDF
2016/07/20Amended Share Trading PolicyPDF
2016/07/20Notice of change of In rests of substantial holderPDF
2016/07/26Change of Director’s Interest NoticePDF
2016/08/04USPTO Grants Allowances for Two PTX-200 PatentsPDF
2016/08/16Section 708A Notice and Appendix 3BPDF
2016/08/31Appendix 4E and Annual ReportPDF
2016/08/31Key to Disclosures Corporate Governance Council Principles and RecommendationsPDF
2016/09/12Appendix 3B - New issue announcement,
application for quotation of additional securities
and agreement
PDF
2016/09/13Rodman and Renshaw PresentationPDF
2016/09/26Moffitt Cancer Center Doses First Patient
in Phase 1b/2 Breast Trial
PDF
2016/10/19RESPONSE TO PRICE QUERYPDF
2016/10/28September 2016 Appendix 4CPDF
2016/10/28Notice of Annual General Meeting - Explanatory Statement and Proxy FormPDF
2016/11/02Receipt of R&D Tax RebatePDF
2016/11/09Appendix 3Y -
Change of Director’s Interest Notice
PDF
2016/11/30RESULTS OF ANNUAL GENERAL MEETINGPDF
2016/12/08Phase 1b/2 Ovarian Trial Commences 2nd Dose EscalationPDF
2016/12/14First Patient Dosed on Phase 1b/2 AML TrialPDF
2016/12/16Change of Registry AddressPDF
2016/12/21New issue announcement,
application for quotation of additional securities
and agreement
PDF
2016/12/21Change of Director’s Interest NoticePDF
2017/09/13Prescient Therapeutics Presents at the
18th Annual Rodman & Renshaw Global Investment Conference in New York
PDF
DATEHEADLINEDOWNLOAD
2015/01/29Appendix 3YsPDF
2015/01/30December 2014 Appendix 4CPDF
2015/02/03Appointment and Resignation of Company Secretary and
Change to Registered Office
PDF
2015/02/09Prescient Therapeutics Acquires Exclusive Worldwide License
for Cancer Biomarker p27
PDF
2015/02/23Prescient Therapeutics Granted Key U.S. Patents for Novel Cancer
Compound PTX-200
PDF
2015/02/27Appendix 4D - Half-year reportPDF
2015/03/03Prescient Therapeutics to Present at 27th Annual Roth
Conference
PDF
2015/03/10Roth ConferencePDF
2015/04/01Prescient Therapeutics Receives Approval from U.S. FDA to
Transfer IND Sponsorship for Lead Drug Candidate PTX-200
PDF
2015/04/21Encouraging Pre-Clinical Data Presented at U.S. Cancer MeetingPDF
2015/04/28International Oncology Executive Appointed Prescient Chief Medical OfficerPDF
2015/04/29March 2015 Appendix 4CPDF
2015/04/30Edison Investment Research
Initiates Coverage
PDF
2015/05/26Distinguished Moffitt Cancer Center Scientist Appointed Chief
Scientific Officer
PDF
2015/05/27New issue announcement, application for quotation of additional securities and agreementPDF
2015/06/10US FDA Reactivates Prescient’s IND for PTX‐100 Breast Cancer TrialPDF
2015/06/23Prescient Issues shares for Milestone 1 Achievement – Pathway acquisitionPDF
2015/06/23Section 708A Cleansing Statement and App 3bPDF
2015/06/26Appendix 3Y - Change of Director’s Interest NoticePDF
2015/06/26Becoming a Substantial HolderPDF
2015/06/26Change in Substantial HoldingPDF
2015/06/29IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PrescientPDF
2015/07/30June 2015 Appendix 4CPDF
2015/08/12Prescient Shareholder NewsletterPDF
2015/08/21Proposed Grant of Options to Non-Executive DirectorsPDF
2015/08/26PTX-200 PHASE 1B/2 CLINICAL TRIAL UPDATEPDF
2015/08/28Appendix 4E and Annual ReportPDF
2015/08/28Key to Disclosures Corporate Governance Council Principles and RecommendationsPDF
2015/08/31Intellectual Property Update – Two New Patents granted to Protect Lead - Asset PTX‐200PDF
2015/09/01PTX Chief Scientific Officer named among Top 20 Translational Researchers by NaturePDF
2015/10/05Notice of Annual General Meeting
and Explanatory Statement
PDF
2015/10/15Prescient Announces Executive Management ChangePDF
2015/10/15Final Director’s Interest NoticePDF
2015/10/27Intellectual Property UpdatePDF
2015/10/29Cleansing Notice – Share purchase planPDF
2015/10/29Share Purchase Plan fully underwritten up to target amount of $1.03 millionPDF
2015/10/29SPP Offer DocumentPDF
2015/10/30September 2015 Appendix 4CPDF
2015/11/02Share purchase plan – documentation issued to shareholdersPDF
2015/11/04New Investor PresentationPDF
2015/11/04RESULTS OF ANNUAL GENERAL MEETINGPDF
2015/11/09PTX Shareholder NewsletterPDF
2015/11/18Share Purchase Plan ResultsPDF
2015/11/20Release of Securities from EscrowPDF
2015/11/23Share Purchase Plan CompletionPDF
2015/11/25Additional Placement Raises $1.0 millionPDF
2015/11/25Appendix 3Y - Change of Director’s Interest NoticePDF
2015/11/25Notice of change of interests of substantial holderPDF
2015/11/26MD Anderson Leukaemia Expert Joins PTX Scientific Advisory BoardPDF
2015/11/30H. Lee Moffitt Cancer Center Leukaemia Oncologist
Joins PTX Scientific Advisory Board
PDF
2015/11/30ASX Section 708A notice & App 3BPDF
2015/12/01Notice of change of interests of substantial holderPDF
2015/12/01Dec 15 Investor PresentationPDF
2015/12/03Notice of initial substantial shareholderPDF
2015/12/08Appendix 3Y - Change of Director’s Interest NoticePDF
2015/12/11Appendix 3B - New issue announcement,
application for quotation of additional securities
and agreement
PDF